Angelini seeks US beachhead with $4.1bn Catalyst buy
Angelini has agreed to buy Catalyst Pharma for up to $4.1bn, its first acquisition since 2021, which would mark its entry into the US market.
Lilly inflates US facility investment spending by $4.5bn
Having already committed last year to capital investments of $27 billion in the US to ward off the threat of tariffs, Eli Lilly has upped the ante.
Why biohackers are ditching vague health metrics
Precision diagnostics enable targeted therapeutics.
CellCentric pockets $220m for blood cancer programme
CellCentric has raised $220 million in a Series D financing that will help fund pivotal trials of p300/CBP inhibitor inobrodib in multiple myeloma.
Featured Content
Latest News
Views & Analysis
Deep Dive
White Papers & Webinar
Podcasts & Video
Partner Content
Navigating Change: Key Industry Insights at PHARMAP 2026
PHARMAP returns in 2027 in Berlin, Germany, with Bayer as the Host Sponsor
Xcovery Partners with EVERSANA to Commercialize Lung Cancer ...
EVERSANA will provide comprehensive end-to-end commercialization services for Xcovery
Axtria Acquires Conexus Solutions, Uniting Agentic AI and CR...
Axtria Inc., a global leader in AI-first data analytics solutions for the life sciences industry, today announced the acquisition of Conexus Solutions
PHARMAP 2026: From Vendors to Strategic Partners
Strategic Partnerships at PHARMAP 2026 – Big Pharma’s Shift Toward CDMOs and CMOs
WOMA 2026: Steering the Future of Pharma Strategy
The WOMA Forum is not merely a conference. It's a convergence point for decision-makers